Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In

  Pfizer Announces Availability Of Quillivant XR™ (methylphenidate
  hydrochloride) CII For Extended-Release Oral Suspension In The United States

The First Once-Daily, Extended-Release Liquid Medication for the Treatment of
                     ADHD is Now Available in Pharmacies

Business Wire

NEW YORK -- January 14, 2013

Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate
hydrochloride) CII for extended-release oral suspension is now available in
the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD).
Quillivant XR is the first once-daily, extended-release liquid methylphenidate
for ADHD and is now available by prescription.

“In order to effectively treat patients with chronic conditions such as ADHD,
it is important to consider individual patient needs, including options for
medication administration,” said Ann Childress, M.D., president of the Center
for Psychiatry and Behavioral Medicine, Las Vegas, who was an investigator in
the Quillivant XR laboratory classroom study. “As the first once-daily,
extended-release liquid medication for patients with ADHD, Quillivant XR
represents a new alternative to other ADHD treatments.”

Quillivant XR was approved by the U.S. Food and Drug Administration (FDA) on
September 27, 2012 for the treatment of ADHD in patients aged 6 years and
above. The efficacy of Quillivant XR was evaluated in a randomized,
double-blind, placebo-controlled, crossover, multicenter, laboratory classroom
study of 45 children with ADHD. Quillivant XR significantly improved ADHD
symptoms compared to placebo at the primary endpoint of four hours post-dose,
and in a secondary analysis, showed significant improvement at every time
point measured, from 45 minutes to 12 hours after dosing.

ADHD is one of the most common neurobehavioral disorders in the U.S.^1
According to the Centers for Disease Control and Prevention’s 2007 data, about
one in ten children aged 4 – 17 in the U.S. had at any time in their life
received a diagnosis of ADHD.^1 Patients with ADHD may suffer from symptoms
such as difficulty paying attention, impulsivity and being overly active in
some cases.^2 The condition can last into adulthood.^3 Although there are many
treatment options for ADHD, until Quillivant XR there was no once-daily,
extended-release liquid option for the treatment of this condition.

“Pfizer is pleased to provide patients and their caregivers with a new option
to help manage this challenging condition,” said Sam Azoulay, M.D., senior
vice president of medical and development for Pfizer’s Emerging Markets and
Established Products Business Units. “We also recognize that caring for and
treating a child with ADHD goes beyond medication. We look forward to working
with mothers and other caregivers of children with ADHD to provide meaningful
resources to the ADHD community.”

Pfizer acquired NextWave Pharmaceuticals on November 27, 2012. Quillivant XR
was developed in conjunction with NextWave’s manufacturing partner, Tris
Pharma, using Tris Pharma’s patent-protected drug delivery platform. For more
information, please visit

Pfizer plans to offer Quillivant XR to patients in need through our Pfizer
Helpful Answers^® program. Pfizer Helpful Answers is Pfizer’s family of
patient-assistance programs that helps eligible patients in the U.S. in need
get access to their Pfizer medicines. In 2011, Pfizer Helpful Answers helped
more than 1 million patients receive over 7.8 million Pfizer prescriptions
through our programs. For more information, call Pfizer Helpful Answers
toll-free at 1-866-706-2400 or visit

About Quillivant XR


Quillivant XR is a federally controlled substance (CII) because it can be
abused or lead to dependence. Keep Quillivant XR in a safe place to prevent
misuse and abuse. Selling or giving away Quillivant XR may harm others and is
against the law. Tell your doctor if you or your child have (or have a family
history of) ever abused or been dependent on alcohol, prescription medicines,
or street drugs.

Quillivant XR should not be taken if you or your child are allergic to
methylphenidate hydrochloride, or any of the ingredients in Quillivant XR, or
are taking or have taken within the past 14 days an antidepression medicine
called a monoamine oxidase inhibitor or MAOI.

Heart-related problems have been reported with methylphenidate hydrochloride
and other stimulant medications:

  *Sudden death in patients who have heart problems or heart defects
  *Stroke and heart attack in adults
  *Increased blood pressure and heart rate

Your doctor should check you or your child’s blood pressure and heart rate
regularly during treatment with QUILLIVANT XR.

Mental (psychiatric) problems can be caused or worsened by methylphenidate
hydrochloride and other stimulant medications:

  *New or worse behavior or thought problems
  *New or worsening bipolar symptoms
  *New or worsening psychotic symptoms (such as hearing voices, believing
    things that are not true, are suspicious)

Call your doctor right away if you or your child have any heart-related
symptoms such as chest pain, shortness of breath or fainting or new or
worsening mental (psychiatric) symptoms or new manic symptoms while taking
Quillivant XR.

Quillivant XR may not be right for you. Tell your doctor if:

  *You or your child have heart problems, heart defects, or high blood
  *You or your child have mental problems including psychosis (hearing
    voices, believing things that are not true, suspicious), mania, bipolar
    illness, or depression or about a family history of suicide, bipolar
    illness or depression
  *You are pregnant or plan to become pregnant. It is not known if Quillivant
    XR will harm your unborn baby. Talk to your doctor if you are pregnant or
    plan to become pregnant
  *You are breastfeeding or plan to breast feed. Quillivant XR passes into
    your breast milk. You and your doctor should decide if you will take
    Quillivant XR or breast feed

Possible serious side effects of Quillivant XR are heart-related problems and
mental problems, as well as slowing of growth (height and weight) in children.
Children should have their height and weight checked often while taking
QUILLIVANT XR. QUILLIVANT XR treatment may be stopped if a problem is found
during these check-ups.

Common side effects include:

  *Decreased        *Vomiting         *Mood swings       *Blurred vision
    appetite         *Trouble          *Agitation         *Increased blood
  *Weight loss        sleeping         *Irritability        pressure
  *Nausea          *Anxiety         *Dizziness        *Fast heart beat
  *Stomach pain     *Nervousness      *Shaking           *Increased
  *Dry mouth        *Restlessness       (tremor)            sweating

Talk to your doctor if you or your child have side effects that are bothersome
or do not go away.

This is not a complete list of possible side effects. Ask your doctor or
pharmacist for more information.


Quillivant XR is a central nervous system (CNS) stimulant prescription
medicine. Quillivant XR is used for the treatment of Attention Deficit
Hyperactivity Disorder (ADHD). Quillivant XR may help increase attention and
decrease impulsiveness and hyperactivity in patients with ADHD.

Please see full Prescribing Information and Medication Guide, including BOXED
WARNING regarding Abuse and Dependence, at

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit or call 1-800-FDA-1088.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for quality,
safety and value in the discovery, development and manufacturing of medicines
for people and animals. Our diversified global health care portfolio includes
human and animal biologic and small molecule medicines and vaccines, and many
of the world's best-known consumer products. Every day, Pfizer colleagues work
across developed and emerging markets to advance wellness, prevention,
treatments and cures that challenge the most feared diseases of our time.
Consistent with our responsibility as the world's leading biopharmaceutical
company, we also collaborate with health care providers, governments and local
communities to support and expand access to reliable, affordable health care
around the world. For more than 150 years, Pfizer has worked to make a
difference for all who rely on us. To learn more about our commitments, please
visit us at


1. Centers for Disease Control and Prevention. Increasing prevalence of
parent-reported attention deficit/hyperactivity disorder among children –
United States, 2003 and 2007. MMWR. 2010;59(44):1439–1443.

2. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders: DSM-IV-TR. Washington: American Psychiatric Association;

3. Kessler R, Adler L, Barkley R, et al. The prevalence and correlates of
adult ADHD in the United States: Results from the National Comorbidity Survey
replication. Am. J. Psychiatry. 2006;163(4):716–23.


Pfizer Inc.
Media Contact:
Lauren Starr, 212-733-2798
Investor Contact:
Suzanne Harnett, 212-733-8009
Press spacebar to pause and continue. Press esc to stop.